Perspectives
Biosimilar Pipeline Quarterly Update: September 2023
Critical updates in an ever-changing environment
September 25, 2023This quarterly pipeline wrap-up provides a review of newly approved biosimilars, an update on the biosimilar pipeline and news of note on biosimilars in the approval process. See separate articles for updates on traditional drugs, specialty drugs and cell/gene therapies.
New Drug Information
- None
New Indications
- None
Biosimilar Product Full Approvals in the Past Twelve Months
| Generic Name | Brand Name | Reference
Product |
Manufacturer | Indication(s) | Route of Administration | Month Approved |
| natalizumab-sztn | Tyruko™ | Tysabri® | Polpharma/Sandoz | Multiple Sclerosis and Crohn’s disease | IV | August 2023 |
| adalimumab-aaty | Yuflyma® | Humira® | Celltrion | Autoimmune | SC | May 2023 |
| adalimumab-aacf | Idacio® | Humira® | Fresenius | Autoimmune | SC | December 2022 |
| insulin glargine-aglr
Interchangeable biosimilar |
Rezvoglar® | Lantus® | Eli Lilly | Diabetes | SC | November 2022 |
Biosimilar Pipeline
| Generic Name | Brand Name | Manufacturer | Indication(s) | Route of Administration | Anticipated Approval date* |
| Oncology | |||||
| FKB238 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Centus Biotherapeutics | Oncology | IV | 2023 |
| BAT-1706 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Bio-thera solutions | Oncology | IV | 2023 |
| SB8 (bevacizumab biosimilar) | Aybintio ™ (Avastin® biosimilar) | Samsung Bioepis/ Merck | Oncology | IV | 2024 |
| HLX02 (trastuzumab biosimilar) | Zercepac® (Herceptin® biosimilar) | AccordBioPharma (Intas)/ Shanghai Henlius Biotech | Oncology | IV | 2023 |
| Blood Modifiers | |||||
| pegfilgrastim | Lupifil-p® (Neulasta® biosimilar) | Lupin | Neutropenia | SC | 2023 |
| pegfilgrastim | Lapelga® (Neulasta® biosimilar) | Apotex/Accord | Neutropenia | SC | 2023 |
| pegfilgrastim | Udenyca® OBI (Neulasta biosimilar) | Coherus BioSciences | Neutropenia | On body device | 2023 |
| filgrastim | Grastofil® (Neupogen® biosimilar) | Apotex/Accord | Neutropenia | SC | 2023 |
| Ophthalmology | |||||
| MYL1701P (aflibercept) | Yesafili™ (Eylea® biosimilar) | Mylan | Diabetic macular edema | Eye injection | 2023 |
| CT-P42 | N/A (Eylea® biosimilar) | Celltrion | Diabetic macular edema | Eye injection | 2024 |
| FYB203 | N/A (Eylea® biosimilar) | Formycon/Klinge | Diabetic macular edema | Eye injection | 2024 |
| ranibizumab | Xlucane (Lucentis® biosimilar) | Xbrane/Bausch | Age-related macular degeneration | Eye injection | 2024 |
| Autoimmune | |||||
| MSB11456 (tocilizumab) | N/A (Actemra® IV/SC biosimilar) | Fresenius | Autoimmune | IV/SC | 2023 |
| BIIB800 (tocilizumab) | N/A (Actemra® IV/SC biosimilar) | Biogen | Autoimmune | IV/SC | 2023 |
| ABP654
(ustekinumab) |
N/A (Stelara® SC biosimilar) | Amgen | Autoimmune | SC | 2023 |
| AVT04
(ustekinumab) |
N/A (Stelara® SC biosimilar) | Alvogen/Alvotech | Autoimmune | SC | 2023 |
| Immunosuppressant | |||||
| Bone Health | |||||
| GP2411 (denosumab) | N/A (Prolia® biosimilar) | Sandoz | Osteoporosis | SC | 2023 |
Related news
Perspectives
August 28, 2024
Clinical News: August 2024
Your monthly source for drug information highlights
Perspectives
August 28, 2024
Drug Approvals Monthly Update: August 2024
This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…
Perspectives
August 27, 2024
Expert Clinical Network Insights: August 2024
A look into our Expert Clinical Network (ECN) — part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance